既往结核患者中(重新)启用TNF拮抗剂与JAK抑制剂的系统综述
该系统综述检索PubMed和Cochrane Library至2023年12月11日,纳入67篇报告368例既往或现患结核患者重新启用TNF拮抗剂后14例(3.8%,95%CI 2.1-6.3%)出现结核复发,中位复发时间8.5个月;JAK抑制剂相关11篇报告中仅1例(9.1%,95%CI 0.2-41.3%)在启用ruxolitinib后10个月出现结核再激活。作者认为重新启用可能相对安全。
要点
- 368例重新启用TNF拮抗剂的结核患者中14例(3.8%,95%CI 2.1-6.3%)出现结核复发,中位时间8.5个月。
- JAK抑制剂相关11篇报告仅1例(9.1%,95%CI 0.2-41.3%)在启用ruxolitinib后10个月出现结核再激活。
- 94例用TNF拮抗剂及2例暂用JAK抑制剂处理矛盾反应的患者中,无微生物学失败或结核症状加重的报告。
核心结论
- 对当前或既往结核且需进一步治疗基础疾病的患者,重新启用TNF拮抗剂和JAK抑制剂可能相对安全。
研究设计与样本
- 系统综述,检索PubMed和Cochrane Library至2023年12月11日,纳入随机对照试验、前瞻性和回顾性队列研究、病例报告和病例系列,不论质量均纳入。
主要发现
- 筛查5018篇文章后纳入67篇,报告368例因基础疾病重新启用TNF拮抗剂的结核患者,中位年龄42.5岁(95%CI 40.4-42.5),有性别记录者中女性占36.6%(n=74)。
- 14例(3.8%,95%CI 2.1-6.3%)在重新启用抗TNF治疗后中位8.5个月(IQR 6.8-14.8个月)出现结核复发。
- 筛查251篇文章后纳入11篇报告因基础疾病重新启用JAK抑制剂的结核患者,中位年龄62岁(IQR 48.5-68.5岁),女性45.5%(n=5);仅1例(9.1%,95%CI 0.2-41.3%)在启用ruxolitinib后10个月出现结核再激活。
- 另分析94例用TNF拮抗剂和2例暂用JAK抑制剂预防或治疗矛盾反应的患者,无出版物报告微生物学失败或结核相关症状加重。
临床怎么用
- 作者认为,对当前或既往结核且需进一步治疗基础疾病的患者,重新启用TNF拮抗剂和JAK抑制剂可能相对安全。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) is a common complication associated with treatment with tumour necrosis factor (TNF) antagonists and Janus kinase (JAK) inhibitors. However, there is uncertainty about the risk of TB relapse in patients with TB and comorbidities requiring treatment with these agents. OBJECTIVES: To assess the risk of TB relapse in patients (re-)started on TNF antagonists or JAK inhibitors. METHODS: Systematic review. DATA SOURCES: PubMed and Cochrane Library databases until 11 December 2023. STUDY ELIGIBILITY CRITERIA: Randomized control trials, prospective and retrospective cohort studies, case reports and case series. PARTICIPANTS: Patients with current or previous TB who were (re-)started on TNF antagonists or JAK inhibitors. INTERVENTIONS: (Re-)introduction of TNF antagonists and JAK inhibitors. ASSESSMENT OF RISK OF BIAS: All studies meeting entry criteria were included regardless of quality. METHODS OF DATA SYNTHESIS: Categorical data are presented as frequencies and percentages. For non-normally distributed aggregated data, we calculated the pooled weighted median with 95% CI. For individual patient data, the median and interquartile range (IQR) were calculated. RESULTS: Of 5018 articles screened for eligibility, 67 publications reporting on 368 TB patients who (re-)initiated treatment with TNF antagonists for underlying diseases were included. The median age was 42.5 years (95% CI: 40.4-42.5) and the proportion of female patients was 36.6% (n = 74) of patients whose sex was reported. A total of 14 patients (3.8%, 95% CI: 2.1-6.3%) developed TB relapse after a median of 8.5 months (interquartile range, 6.8-14.8 months) following (re-)initiation of anti-TNF treatment. Furthermore, among 251 articles screened for eligibility, 11 reports on TB patients who were (re-)started on JAK inhibitors for underlying diseases were identified. The median age was 62 years (interquartile range, 48.5-68.5 years) and 45.5% (n = 5) were female. Only one patient (9.1%; 95% CI: 0.2-41.3%) had TB reactivation 10 months after starting treatment with ruxolitinib. In addition, 94 patients who were treated with TNF antagonists and two patients temporarily treated with JAK inhibitors for the prevention or treatment of paradoxical reactions were analysed. None of the publications reported microbiological failure or worsening of TB-related symptoms. CONCLUSIONS: (Re-)initiation of TNF antagonists and JAK inhibitors may be relatively safe in patients with current or previous TB and the need for further treatment of underlying diseases.
引用
- Brehm TT, Reimann M, Köhler N, et al. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review. Clin Microbiol Infect. 2024. PMID: 38663653. doi:10.1016/j.cmi.2024.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。